Fintel reports that on July 17, 2025, Needham downgraded their outlook for Clearside Biomedical (NasdaqGM:CLSD) from Buy to Hold. Analyst Price Forecast Suggests 571.05% Upside As of July 16, 2025, ...

Fintel reports that on July 18, 2025, HC Wainwright & Co. downgraded their outlook for Clearside Biomedical (NasdaqGM:CLSD) from Buy to Neutral. Analyst Price Forecast Suggests 832.20% Upside As of ...

Clearside Biomedical CLSD shares fell 25.4% to $0.45. The market value of their outstanding shares is at $46.7 million. Sonnet BioTherapeutics SONN stock fell 21.06% to $6.15.

Three big catalysts are gearing up to hit the markets at month’s end. Matt Maley is going live this Sunday at 1 PM ET to reveal how he’s trading short-term setups across financials, tech, defense, and ...

Continued Global Expansion and Validation of Clearside’s Suprachoroidal Space Injection Platform Featuring its Commercially Proven SCS Microinjector® - ALPHARETTA, Ga., July 23, 2025 (GLOBE NEWSWIRE) ...

Investing.com - Stifel 将 Clearside Biomedical (NASDAQ: CLSD) 的评级从买入下调至持有，并将目标价从 8.00 美元大幅削减至 2.00 美元，原因是该公司面临严重的财务限制。根据 ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research ...

此次降级是在Clearside决定暂停其研发项目后做出的，包括其在10月份显示出有希望的2期数据的CLS-AX湿性AMD治疗方案。自发布这些结果以来，该公司一直无法筹集足够的资金来支持昂贵的3期项目。根据 InvestingPro ...

Investing.com -- Clearside Biomedical, Inc. (NASDAQ: CLSD) stock fell 0.7% on Thursday after the company announced plans to explore strategic alternatives to advance its proprietary Suprachoroidal ...

Clearside Biomedical will divert all employees to a consulting status and halt research-and-development, allowing the eye-care biotechnology firm to conserve cash during a search for a deal or other ...

ALPHARETTA, Ga. - Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company with a market capitalization of $65 million and impressive gross profit margins of 89%, announced Thursday ...

(RTTNews) - Clearside Biomedical, Inc. (CLSD) announced plans to explore a full range of strategic alternatives to advance its SCS platform and drug development pipeline to maximize stockholder ...